Clinical Trial Update: Resminostat (YHI-1001) in Combination With Sorafenib in Asian Patients With Advanced Hepatocellular Carcinoma (HCC) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for Resminostat (YHI-1001) in combination with Sorafenib in Asian patients with advanced hepatocellular carcinoma (HCC) across Phase 1 and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Resminostat (resminostat)
• Sorafenib (Sorafenib)

Snippet

Sponsor: Yakult Honsha Co., LTD | Conditions: Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: COMPLETED